New discovery on the causes of PAP lung disease can also offer solutions for treating obesity and heart disease. The research group of Associate Professor Alexander Mildner at the University of Turku, ...

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Pulmonary alveoli are tiny bubble-like air sacs at the end of bronchial tubes. They are vital for survival as they exchange oxygen for carbon dioxide. The alveoli are covered by a thin fluid film ...

If a secretion in the lungs’ alveoli is not cleared regularly, breathing difficulties can develop. In a study published in Science Immunology, a team led by Alexander Mildner and Achim Leutz has now ...

The novel agent molgramostim improved pulmonary gas exchange in autoimmune pulmonary alveolar proteinosis, a randomized trial showed. In this rare condition, surfactant builds up in the alveoli as ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic ...

New study in The American Journal of Pathology suggests potential avenues of research to develop new therapies to improve survival and prevent chronic lung disease in COVID-19 and non--COVID-19 acute ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 ...

New discovery on the causes of PAP lung disease can also offer solutions for treating obesity and heart disease. The research group has identified a genetic defect that causes the accumulation of ...